Summary
A substantial reduction in the levels of both total and antigen specific IgE will most likely result in improved symptom scores in atopic individuals. Based on this assumption we initiated a project to study the possibility of reducing levels of circulating and mast cell bound IgE, by inducing a strong autoimmune antibody response against IgE in the host. Bacterially produced fusion proteins containing constant domains two (CH2) and three (CH3) of rat IgE directly linked to the glutathione-S-transferase (GST) protein from Schistosoma japonicum or to the maltose binding protein of Esherichia coli were used as the active components of the allergy vaccine. Injection of either of these fusion proteins together with adjuvant led to the induction of a strong autoimmune anti-IgE response in several IgE low or medium responder strains of rats.
Vaccination of ovalbumin sensitised Wi star rats with the GST- C2C3 fusion protein resulted in a profound decrease in serum IgE levels and later in a nearly complete block in histamine release from mast cells and basophils upon challenge with either a cross-linking polyclonal anti-IgE antiserum or a specific allergen. This shows that it is possible to reduce IgE levels in an animal to such an extent that it gives a clear clinical effect. Recent studies with an extended panel of rat strains including four IgE high responder strains, indicate that induction of the autoimmune response is dependent on the plasma concentration ofIgE before vaccination. A high concentration of IgE has a negative effect on the induction of autoimmunity, most likely by inducing a B-cell tolerance in the host. Vaccinated subjects with very high IgE concentrations thereby responds poorly to the vaccine. Current studies are aimed at overcoming this potential limitation of the vaccination procedure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chang, T. W., Davis, F. M., Sun, N.-G, Sun, C. R. Y, MacGlashan Jr, D. W., and Hamilton, R. G. (1990). Monoclonal antibodies specific for human IgE-producing B-cells: a potential therapeutic for IgE-mediated allergic diseases. Bio/Technology 8, 122–126.
Chen, S.-S., and Katz, D. H. (1983). IgE class-restricted tolerance induced by neonatal administration of soluble or cell-bound IgE. J. Exp. Med. 157, 722–788.
Chen, S.-S., Liu, F.-T., and Katz, D. H. (1984). IgE class-restricted tolerance induced by neonatal administration of soluble or cell-bound IgE, Cellular mechanisms. J. Exp. Med. 160, 953–970.
Davis, F. M., Gossett, L. A., Pinkston, K. L., Liou, R. S., Sun, L. K., Kim, Y. W., Chang, N. T., Chang, T. W., Wagner, K., Bews, J., Brinkmann, V., Towbin, H., Subramanian, N., and Heusser, C. (1993). Can anti-IgE be used to treat allergy? In Springer Semin. Immunopathol. 15, 51–73.
Diaz-Sanchez, D., and Kemeny, D. M. (1991). Generation of a long-lived IgE response in high and low responder strains of rat by co-administration of ricin and antigen. Immunology 72, 297–303.
Haba, S., and Nisonoff, A. (1994). Effect of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J.Immunol. 152, 51–57.
Haba, S., and Nisonoff, A. (1988). Immunological responsiveness of neonatal A/J mice to isotypic determinants of syngeneic IgE. J. Exp. Med. 168, 713–724.
Haba, S., and Nisonoff, A. (1987). Induction of high titers of anti-IgE by immunization of inbred mice with syngeneic IgE. Proc. Natl. Acad. Sci. USA 84, 5009–5013.
Haba, S., and Nisonoff, A. (1990). Inhibition of IgE synthesis by anti-IgE: Role of long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc. Natl. Acad. Sci. USA 87, 3363–3367.
Haba, S., and Nisonoff, A. (1994). Role of antibody and T cells in the long-term inhibition of IgE synthesis. Proc. Natl. Acad. Sci. USA 91, 604–608.
Hellman, L. (1994). Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur. J. Immunol. 24, 415–420.
Helm, B., Kebo, D., Vercelli, D., Glovsky, M., Gould, H., Ishizaka, K., Geha, R., and Ishizaka, T. (1989). Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ε-chain fragment of 76 amino acids. Proc. Natl. Acad. Sci. USA 86, 9465–9469.
Helm, B., Marsh, P., Vercelli, D., Padlan, E., Gould, H., and Geha, R. (1988). The mast cell binding site on human immunoglobulin E. Nature 331, 180–183.
Marshall, J. S., and Bell, E. B. (1985). Induction of an auto-anti-IgE response in rats I. Effects on serum IgE concentrations. Eur. J. Immunol. 15, 272–277.
Marshall, J. S., and Bell, E. B. (1989). Induction of an auto-anti-IgE response in rats III. Inhibition of a specific IgE response. Immunology 66, 428–433.
Marshall, J. S., Prout, S. J., Jaffery, G., and Bell, E. B. (1987). Induction of an auto-anti-IgE response in rats II. Effects on mast cell populations. Eur. J. Immunol. 17, 445–451.
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., and Jardieu, P. M. (1993). Hu-manization of an antibody directed against IgE. J. Immunol. 151, 2623–2632.
Weiss, S., Lehmann, K., Raschke, W. C, and Cohn, M. (1984). Mice completely suppressed for the expression of immunoglobulin k light chain. Proc. Natl. Acad. Sci. USA. 81, 211–215.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hellman, L. (1996). Is Vaccination Against IgE Possible?. In: Sehon, A., HayGlass, K.T., Kraft, D. (eds) New Horizons in Allergy Immunotherapy. Advances in Experimental Medicine and Biology, vol 409. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5855-2_47
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5855-2_47
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7684-2
Online ISBN: 978-1-4615-5855-2
eBook Packages: Springer Book Archive